Sintilimab

Generic Name: Sintilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2072873-06-2

Unique Ingredient Identifier: 8FU7FQ8UPK

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Phase 2

Recruiting

Conditions: Advanced Intrahepatic Cholangiocarcinoma

Interventions: Procedure: Cryoablation
Drug: Sintilimab
Drug: Lenvatinib

First Posted Date: 2023-04-28

Last Posted Date: 2023-05-31

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT05835245

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Phase 2

Active, not recruiting

Conditions: Stomach Neoplasms

Interventions: Drug: Fruquintinib
Drug: Sintilimab

First Posted Date: 2023-04-03

Last Posted Date: 2023-08-30

Lead Sponsor: RenJi Hospital

Target Recruit Count: 30

Registration Number: NCT05795296

Locations: 🇨🇳
Renji Hospital, Shanghai, China

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）

Phase 2

Recruiting

Conditions: Advanced Biliary Tract Cancer

Interventions: Drug: Sintilimab
Drug: Lenvatinib
Procedure: Cryoablation

First Posted Date: 2023-03-23

Last Posted Date: 2023-03-24

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05781074

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Oral Cavity Squamous Cell Carcinoma

Interventions: Radiation: Radiotherapy
Drug: Sintilimab

First Posted Date: 2023-03-01

Last Posted Date: 2023-03-01

Lead Sponsor: Xin-Hua Xu

Target Recruit Count: 70

Registration Number: NCT05749042

Locations: 🇨🇳
Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Phase 1

Recruiting

Conditions: Advanced Biliary Tract Cancer

Interventions: Drug: IBI310
Drug: sintilimab

First Posted Date: 2022-12-16

Last Posted Date: 2023-04-03

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 20

Registration Number: NCT05653180

Locations: 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China

First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial

Phase 3

Recruiting

Conditions: Advanced Non-squamous Non-Small-Cell Lung Cancer

Interventions: Drug: Sintilimab

First Posted Date: 2022-12-13

Last Posted Date: 2022-12-13

Lead Sponsor: Qianfoshan Hospital

Target Recruit Count: 60

Registration Number: NCT05648071

Locations: 🇨🇳
The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Phase 2

Recruiting

Conditions: Neuroendocrine Tumor Grade 3
Neuroendocrine Carcinoma
Pancreatic Carcinoma

Interventions: Drug: Surufatinib
Drug: Sintilimab

First Posted Date: 2022-11-25

Last Posted Date: 2022-11-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 60

Registration Number: NCT05627427

Locations: 🇨🇳
Rui Liu, Tianjin, Tianjin, China

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Disitamab Vedotin
Drug: Sintilimab
Drug: S-1
Procedure: Intraperitoneal chemotherapy with paclitaxel

First Posted Date: 2022-11-25

Last Posted Date: 2022-11-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05627414

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Stomach Neoplasms

Interventions: Drug: Fruquintinib
Drug: Sintilimab

First Posted Date: 2022-11-23

Last Posted Date: 2022-11-23

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 29

Registration Number: NCT05625737

Locations: 🇨🇳
Wuhan Union Hospital, China, Wuhan, Hubei, China

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Not Applicable

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: HAIC
Drug: Sintilimab
Drug: Lenvatinib

First Posted Date: 2022-11-18

Last Posted Date: 2022-11-18

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 60

Registration Number: NCT05621499

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy